Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%

EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24

Zota Health Care Q2 FY25 revenue up 48.6%

Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%

Ecovyst launches AlphaCat advanced silicas products for biocatalysis applications

Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential

Univar Solutions becomes exclusive distributor of SD Head USA Pharmaceutical excipients in North America

Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions

IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr

Total Income in Q2 FY25 stood at Rs. 532.18 crore

Merck receives positive EU CHMP opinion for pembrolizumab plus chemotherapy as first-line treatment for unresectable non-epithelioid MPM

Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial

Shilpa Medicare Q2 FY25 consolidated PAT up 1,008% at Rs. 18 Cr

Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024

Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS

AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia

Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial

AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr

We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%